Outcomes and Risk Factors for Influenza and Respiratory Syncytial Virus Lower Respiratory Tract Infections and Mortality in Patients With Lymphoma or Multiple Myeloma: A 7-Year Retrospective Cohort Study - Top-Institutions - MDSpire

Outcomes and Risk Factors for Influenza and Respiratory Syncytial Virus Lower Respiratory Tract Infections and Mortality in Patients With Lymphoma or Multiple Myeloma: A 7-Year Retrospective Cohort Study

  • By

  • Tali Shafat

  • Daniel De-la-Rosa-Martinez

  • Fareed Khawaja

  • Ying Jiang

  • Amy Spallone

  • Marjorie Vieira Batista

  • Ella Ariza-Heredia

  • Diana Vilar-Compte

  • Sairah Ahmed

  • Melody Becnel

  • Roy F Chemaly

  • March 4, 2025

  • 0 min

Share

Top Institutions in Infectious Disease

Brief introduction explaining scope and methodology.

  • #1

    Fred Hutchinson Cancer Center
    Fred Hutchinson Cancer Center

    Seattle, WA

    Key Differentiators

    • Hematology
    • Infectious Diseases
    • Hematopoietic Cell Transplantation

  • #2

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Hematology-Oncology
    • Infectious Diseases

  • #3

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology
    • Infectious Diseases

  • #4

    National Institutes of Health (NIAID/NIH Clinical Center)
    National Institutes of Health (NIAID/NIH Clinical Center)

    Bethesda, MD

    Key Differentiators

    • Infectious Diseases
    • Immunology
    • Hematology

  • #5

    University of Washington Medical Center
    University of Washington Medical Center

    Seattle, WA

    Key Differentiators

    • Hematology
    • Infectious Diseases

Original Source(s)

Outcomes and Risk Factors for Influenza and Respiratory Syncytial Virus Lower Respiratory Tract Infections and Mortality in Patients With Lymphoma or Multiple Myeloma: A 7-Year Retrospective Cohort Study

  • by Tali Shafat, Daniel De-la-Rosa-Martinez, Fareed Khawaja, Ying Jiang, Amy Spallone, Marjorie Vieira Batista, Ella Ariza-Heredia, Diana Vilar-Compte, Sairah Ahmed, Melody Becnel, Roy F Chemaly

  • March 4, 2025

Related Content

Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma

Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy

Treatment Intensity in the Frontline Setting for Transplant-Ineligible Patients With Multiple Myeloma

The management of newly diagnosed transplant-ineligible multiple myeloma remains challenging, in part due to the complexity of treatment decisions for frail patients. Recent subgroup analyses provide insight into whether quadruplet therapy may offer advantages over triplet therapy in this population.